2/25/2010 @ 6:00AM

Drug Companies Disappoint Me Again

I want to believe in America’s pharmaceutical companies. I want to believe that people in these companies believe that the best strategy for success is to do what is best for patients. I want to believe that they are interested in scientific truth and eager to know of any safety issues and ready to share that information with the public.

This week I was disappointed again.

Over the years
GlaxoSmithKline
has repeatedly reassured the public about the safety of its blockbuster diabetes drug Avandia. But this weekend the Senate Finance Committee released a report revealing that inside the company Glaxo’s own experts and advisors were raising concerns about whether the drug could cause heart problems all along.

The report, based on more than 250,000 internal documents, provides a rare and unsettling glimpse into the decision by company executives to deflect safety issues–even as their own experts agreed with conclusions of outside researchers who were warning the public about possible harms.

The documents reveal that company researchers were deeply concerned about the cardiovascular safety of the drug as far back as 2003. The pages of the Senate report read like a spy novel: Glaxo receiving confidential documents leaked by a sympathetic academic who consulted for the company; the company embarking on a campaign to intimidate critics who warned about potential safety issues with the drug; and executives pulling strings to release data early from a scientific study that was supposedly controlled by an “independent” committee of researchers.

While Glaxo was publicly downplaying safety worries, a company statistician indicated that concerns raised by critics, including Cleveland Clinic cardiologist Steven Nissen, were legitimate. In one internal document the head of research states that analyses from the FDA, Nissen and GSK all suggested that Avandia could be causing heart attacks. Meanwhile, Glaxo’s media relations department was telling the public that there was no link between the drug and heart disease.

The story here is less about the drug–the Senate report breaks no new ground about Avandia’s safety issues (even among experts there remains some controversy)–and more about the ethical behavior of a company. What is clear: Glaxo failed to disclose its own concerns even as it sought to discredit outside researchers who were raising questions about the drug.

This type of behavior is eroding the public trust in the pharmaceutical industry. The fix is simple: Once a drug is approved, all data relevant to drug safety should be placed in the public domain and independent investigators across the country should be able to use it. There should be big financial penalties for withholding relevant information. Drug studies sponsored by industry must be truly independent–outside of company control. Companies should give outside investigators independence over every aspect of the study. There are too many examples of companies wresting control of clinical studies from their consultant investigators for reasons that seem more related to product promotion than clinical science.

And on all sides there should be a commitment to protect against the intimidation of academics who are willing to raise questions about the safety and effectiveness of company products. The free flow of information about the effects of drugs and medical devices will best serve the public’s interest.

Dr. Harlan Krumholz is a cardiologist and the Harold H. Hines professor of medicine and epidemiology and public health at Yale University. In the past, he did consulting for plaintiff lawyers suing
Merck
over Vioxx.